Shares of Iovance Biotherapeutics (NASDAQ: IOVA) have been on a roller-coaster ride over the past few days. That's likely because investors don't know what to make of press releases that don't quite jibe with a big disclosure the company recently made regarding CEO Maria Fardis.
On May 18, Fardis notified the company she would be resigning "to pursue other opportunities." That's a little hard to swallow because the company recently reported highly successful clinical trial results.
Image source: Getty Images.
For further details see:
Here's Why Everyone's Talking About Iovance Biotherapeutics